RxDoctor Payments Data

Alan Donsky, MD

Clinical Cardiac Electrophysiology · Dallas, TXNPI 1699734731

Payments from drug & device makers

$40,312in general payments, 2019–2025

Across 411 payments — averaging $98.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$28K
  • Medtronic$8K
  • Abbott$2K
  • Atricure, Inc.$456
  • Novartis$272
  • Biotronik Inc.$157
  • plus $729 from 15 others

What the payments were for

  • Consulting fees$80%
  • Travel & lodging$110%
  • Food & beverage$13,799100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,312 in reported general payments places this provider in the 50th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$316,669
Medicare patients
2,232
Services billed
6,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban413$447,021
XareltoRivaroxaban239$229,953
EntrestoSacubitril/Valsartan55$54,229
MultaqDronedarone Hcl47$50,715
Flecainide Acetate212$8,383
Amiodarone Hcl339$4,191
Metoprolol Succinate268$4,124
Diltiazem 24hr Er (La)Diltiazem Hcl37$3,269
Matzim LaDiltiazem Hcl28$2,516
Diltiazem 24hr Er (Cd)Diltiazem Hcl59$2,398
SotalolSotalol Hcl136$2,084
Metoprolol Tartrate183$1,392
Carvedilol83$760
Losartan Potassium35$448
Lisinopril52$415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$84$447,021413 claims
Johnson & JohnsonXarelto$47$229,953239 claims
NovartisEntresto$272$54,22955 claims
Sanofi-aventis U.S. LLCMultaq$17$50,71547 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →